← back to search

Angela Dispenzieri

Mayo Clinic · US
Area of research
Molecular Biology · Hematology
Research interest
Research interests include Multiple Myeloma Research and Treatments, Amyloidosis: Diagnosis, Treatment, Outcomes, Protein Degradation and Inhibitors, and Chronic Lymphocytic Leukemia Research.
h-index
145
citations
99,559
works
2,485
NIH funding
primary concept
email

Recent publications

Diagnostic Performance and Interpreter Experience of 1-Hour Versus 3-Hour <sup>99m</sup>Tc-HMDP Cardiac Amyloid Radionuclide Imaging: A Prospective, Blinded Comparison.
2026cited by 1position: contributordoi
POD24 is a novel determinant of prognosis in patients with Waldenström macroglobulinemia.
2026cited by 1position: contributordoi
Artificial intelligence-enhanced electrocardiogram findings before and after heart transplantation in cardiac amyloidosis.
2026cited by 0position: contributordoi
Real-World Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated With Front-Line Daratumumab Lenalidomide and Dexamethasone.
2026cited by 0position: contributordoi
Genomic Proximity Mapping for Identification of Chromosomal Aberrations in Multiple Myeloma.
2026cited by 0position: contributordoi
The role of cardiac imaging for diagnosis of cardiac amyloidosis: a systematic review and meta-analysis of test accuracy.
2026cited by 0position: contributordoi
Gene expression-based dissemination score predicts early spread and poor outcomes in multiple myeloma.
2026cited by 0position: contributordoi
Comprehensive analysis of subtype-specific outcomes and management in Castleman disease: a 20-year cohort study.
2026cited by 0position: contributordoi
Determinants of Gastrointestinal Disease Burden and Survival in Systemic AL Amyloidosis.
2026cited by 0position: contributordoi
AL amyloidosis: a real-world experience with CAR T-cell therapy.
2026cited by 0position: contributordoi
Diagnostic Utility of Immunofixation and Free Light Chain Assay in AL Amyloidosis: A Systematic Review and Meta-analysis.
2026cited by 0position: contributordoi
American Society of Hematology (ASH) 2026 Guidelines on Diagnosis of Light Chain Amyloidosis.
2026cited by 0position: contributordoi
A multi-center study of progression-risk and outcomes in solitary bone plasmacytoma with and without marrow involvement.
2026cited by 0position: contributordoi
Elevated non-clonal bone marrow plasma cell fraction at diagnosis is associated with improved outcomes in multiple myeloma.
2026cited by 0position: contributordoi
Biomarkers of Cellular Senescence and their Association with Frailty, Clinical Outcomes, and Survival in Multiple Myeloma
2026cited by 0position: contributordoi
Cardiac Amyloidosis AI‐ECG Model is Useful in Predicting Outcomes in Multiple Myeloma Patients Without Amyloidosis Undergoing Autologous Stem Cell Transplant
Advances in Hematology 2026cited by 0position: contributordoi
Cytogenetics-based Clinical Trajectories in Patients with MRD Negativity Post Autologous Transplant for Multiple Myeloma
2026cited by 0position: contributordoi
Risk of AL Amyloidosis is Associated with Degree of Free Light Chain Elevation and Duration of Exposure
2026cited by 0position: contributordoi
Cardiac amyloidosis detection from a single echocardiographic video clip: a novel artificial intelligence-based screening tool
European Heart Journal 2025cited by 28position: middledoi
Five-Year Results With Patisiran for Hereditary Transthyretin Amyloidosis With Polyneuropathy
JAMA Neurology 2025cited by 25position: middledoi
Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registry
Blood Advances 2025cited by 15position: middledoi
Solitary plasmacytoma: single-institution experience, and systematic review and meta-analysis of clinical outcomes.
2025cited by 10position: contributordoi
Improved survival with daratumumab-CyBorD compared with CyBorD as frontline therapy for AL amyloidosis.
2025cited by 9position: contributordoi
Comparison of progression risk of monoclonal gammopathy of undetermined significance by method of detection.
2025cited by 7position: contributordoi
Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registry.
2025cited by 7position: contributordoi
Development of Imaging Endpoints for Clinical Trials in AL and ATTR Amyloidosis
JACC. Cardiovascular imaging 2025cited by 7position: middledoi
Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis.
2025cited by 5position: contributordoi
Clonal plasma cell proportion in the synthetic phase identifies a unique high-risk cohort in multiple myeloma.
2025cited by 5position: contributordoi
Capillary leak phenotype as a major cause of death in patients with POEMS syndrome.
2025cited by 5position: contributordoi
Risk of lymphoid malignancy associated with cancer predisposition genes.
2025cited by 4position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 194 papers (2019–2026)Shaji K. Kumar · University of Wisconsin–Madison127 papers (2019–2026)Morie A. Gertz · Mayo Clinic124 papers (2016–2026) · 120 papers (2019–2026)Taxiarchis Kourelis · Mayo Clinic100 papers (2019–2026) · 99 papers (2019–2026)Eli Muchtar · Mayo Clinic81 papers (2019–2026)S. Vincent Rajkumar · Sri Ramachandra Medical Centre79 papers (2016–2026)Nelson Leung · Mayo Clinic78 papers (2019–2026) · 77 papers (2019–2026)Francis Buadi · Mayo Clinic in Florida73 papers (2019–2026)Prashant Kapoor · University of Minnesota Rochester57 papers (2020–2026)Moritz Binder · Epigenomics (Germany)53 papers (2019–2026)David Dingli · University College London52 papers (2021–2026)Yi Lin · Ningbo University47 papers (2019–2026)Rahma Warsame · Dana-Farber Cancer Institute45 papers (2019–2026)Joselle Cook · Mayo Clinic36 papers (2021–2026)Wilson Gonsalves · St. Luke's Hospital36 papers (2019–2026)Nadine Abdallah · Minnesota Oncology32 papers (2020–2026)Saurabh Zanwar · University of Minnesota Rochester21 papers (2020–2026)